BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 20039896)

  • 1. A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization.
    Castellone MD; Verrienti A; Magendra Rao D; Sponziello M; Fabbro D; Muthu M; Durante C; Maranghi M; Damante G; Pizzolitto S; Costante G; Russo D; Santoro M; Filetti S
    Clin Endocrinol (Oxf); 2010 Oct; 73(4):529-34. PubMed ID: 20039896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo.
    Oliveira MN; Hemerly JP; Bastos AU; Tamanaha R; Latini FR; Camacho CP; Impellizzeri A; Maciel RM; Cerutti JM
    Thyroid; 2011 Sep; 21(9):975-85. PubMed ID: 21834681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular implications of RET mutations for pheochromocytoma risk in multiple endocrine neoplasia 2.
    Gujral TS; Mulligan LM
    Ann N Y Acad Sci; 2006 Aug; 1073():234-40. PubMed ID: 17102091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.
    Kinlaw WB; Scott SM; Maue RA; Memoli VA; Harris RD; Daniels GH; Porter DM; Belloni DR; Spooner ET; Ernesti MM; Noll WW
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):676-82. PubMed ID: 16343103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma.
    D'Aloiso L; Carlomagno F; Bisceglia M; Anaganti S; Ferretti E; Verrienti A; Arturi F; Scarpelli D; Russo D; Santoro M; Filetti S
    J Clin Endocrinol Metab; 2006 Mar; 91(3):754-9. PubMed ID: 16384843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RET mutation status in medullary thyroid cancer(MTC) patients and the significance of genetic screening for mutations in their immediate relatives--a preliminary report.
    Menon MM; Simha MR
    Indian J Pathol Microbiol; 2005 Apr; 48(2):161-5. PubMed ID: 16758654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Y606C RET mutation causes a receptor gain of function.
    Ercolino T; Lombardi A; Becherini L; Piscitelli E; Cantini G; Gaglianò MS; Serio M; Luconi M; Mannelli M
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):253-8. PubMed ID: 18248647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neural crest and multiple endocrinopathies].
    Pasini A; Michiels FM; Chappuis-Flament S; Geneste O; Rossel M; Fournier L; Feunteun J; Lenoir G; Schuffenecker I; Billaud M
    C R Seances Soc Biol Fil; 1996; 190(5-6):557-67. PubMed ID: 9074721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre.
    Bugalho MJ; Domingues R; Santos JR; Catarino AL; Sobrinho L
    Surgery; 2007 Jan; 141(1):90-5. PubMed ID: 17188172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with RET D631Y mutations most commonly present with pheochromocytoma and not medullary thyroid carcinoma.
    Elston MS; Meyer-Rochow GY; Holdaway I; Conaglen JV
    Horm Metab Res; 2012 May; 44(5):339-42. PubMed ID: 22274720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple endocrine neoplasia type 2 and the RET protooncogene: from bedside to bench to bedside.
    Machens A; Dralle H
    Mol Cell Endocrinol; 2006 Mar; 247(1-2):34-40. PubMed ID: 16343738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [C634R mutation of the protooncongene RET and molecular diagnosis in multiple endocrine neoplasia type 2 in a large Moroccan family].
    Benazzouz B; Hafidi A; Benkhira S; Chraibi A; Kadiri A; Hilal L
    Bull Cancer; 2008 Apr; 95(4):457-63. PubMed ID: 18495576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations.
    Learoyd DL; Gosnell J; Elston MS; Saurine TJ; Richardson AL; Delbridge LW; Aglen JV; Robinson BG
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):636-41. PubMed ID: 16343097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The synergy of germline C634Y and V292M RET mutations in a northern Chinese family with multiple endocrine neoplasia type 2A.
    Yang Z; Qi X; Gross N; Kou X; Bai Y; Feng Y; Wang B; Zafereo ME; Li G; Sun C; Li H; Chen X; Huang Z
    J Cell Mol Med; 2020 Nov; 24(22):13163-13170. PubMed ID: 32989896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation.
    Milos IN; Frank-Raue K; Wohllk N; Maia AL; Pusiol E; Patocs A; Robledo M; Biarnes J; Barontini M; Links TP; de Groot JW; Dvorakova S; Peczkowska M; Rybicki LA; Sullivan M; Raue F; Zosin I; Eng C; Neumann HP
    Endocr Relat Cancer; 2008 Dec; 15(4):1035-41. PubMed ID: 18794325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RET genetic screening in patients with medullary thyroid cancer: the Moroccan experience.
    Abdelhakim A; Barlier A; Kebbou M; Benabdeljalil N; Timinouni M; Taoufiq F; Roche C; El Antri S
    J Cancer Res Ther; 2009; 5(3):198-202. PubMed ID: 19841562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional characterization of the MTC-associated germline RET-K666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism.
    Borrello MG; Aiello A; Peissel B; Rizzetti MG; Mondellini P; Degl'Innocenti D; Catalano V; Gobbo M; Collini P; Bongarzone I; Pierotti MA; Greco A; Seregni E
    Endocr Relat Cancer; 2011 Aug; 18(4):519-27. PubMed ID: 21690267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Change in the spectrum of RET mutations diagnosed between 1994 and 2006.
    Frank-Raue K; Rondot S; Schulze E; Raue F
    Clin Lab; 2007; 53(5-6):273-82. PubMed ID: 17605401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RET proto-oncogene testing in infants presenting with Hirschsprung disease identifies 2 new multiple endocrine neoplasia 2A kindreds.
    Fialkowski EA; DeBenedetti MK; Moley JF; Bachrach B
    J Pediatr Surg; 2008 Jan; 43(1):188-90. PubMed ID: 18206480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.